ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired MedPass International, the leading European medical device CRO, regulatory and reimbursement consultancy, that specialises in medical device development and market access.
This acquisition, concluded in late January, further enhances ICON’s Medical Device and Diagnostic Research Services, through the addition of new regulatory and clinical capabilities in Europe. The integration of MedPass International’s services brings noted expertise in complex class 3 medical devices, interventional cardiology and structural heart devices.
Founded in 1991 and headquartered in Paris, MedPass International is the leading European Medical Device CRO and consultancy. The company has served more than 1,000 medical device companies, from start-ups to multi-nationals, and has contributed to the development of hundreds of innovative devices including a number of breakthrough technologies.
Sarah Sorrell, President and CEO, MedPass International, said: “As the leader in Medical Device Regulation and Clinical Development in Europe, MedPass is delighted to be joining ICON to become the global service provider of choice in Medtech Devices and Diagnostics.”
“The acquisition of MedPass International deepens our existing advisory capabilities, particularly in medical device regulation,” commented Dr. Steve Cutler, Chief Executive Officer, ICON plc. “The medical device CRO market is experiencing strong growth due to technical innovation, changing regulations and increasing levels of outsourcing. This addition broadens our medical device footprint and staff headcount across Europe, positioning us among the global leaders in this market.”
Fairmount Partners, a leading middle-market investment bank in the Pharmaceutical Services industry, served as financial advisor to ICON on the transaction.
About MedPass International
Founded in 1991 by Sarah Sorrel, MedPass is the leading European Medical Device CRO and Regulatory and Reimbursement Consultancy. MedPass has helped to advance the development of breakthrough medical device technologies by offering a broad range of strategic and operational services tailored to meet the needs of clients around the globe. MedPass is headquartered in Paris and delivers its services through a team of around 100 staff (a mix of full-time and contract staff). More details on MedPass can be found on the company website http://medpass.org.
About ICON plc
ICON plc is a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies and device development from early phase product development through pre-market and commercialization studies. With headquarters in Dublin, Ireland, ICON currently operates from 97 locations in 40 countries and has approximately 14,650 employees as at December 31, 2019. Further information is available at www.iconplc.com.
About Fairmount Partners
Fairmount Partners is an independent merger and acquisition advisory firm focused on emerging growth and middle market companies. Fairmount helps its clients complete mergers and acquisitions; raise funds for growth, acquisitions and liquidity; and design and improve their corporate development strategies. Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises, and global public companies. Since 2003, Fairmount has completed more than 220 transactions, representing over $10 billion in aggregate value, in 20 countries throughout North and South America, Europe, Asia and Australia. Further information is available at www.fairmountpartners.com.
